The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis

• Published in: Journal of clinical medicine Vol. 12; no. 13; p. 4179
• Main Authors: Adamczyk, Michał, Bartosińska, Joanna, Raczkiewicz, Dorota, Michalak-Stoma, Anna, Krasowska, Dorota
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.06.2023; MDPI
• Subjects: Antigens; Biopharmaceutics; Clinical medicine; Cytokines; Dermatitis; Dermatology; Development and progression; Disease; Drug therapy; Flow cytometry; Health aspects; Immune system; Ligands; Lymphocytes; Monoclonal antibodies; Physiological aspects; Psoriasis; Psoriatic arthritis; Tumors; Poland; United States > US; biologic treatment; systemic treatment; psoriasis; immune checkpoint

The programmed death-1 (PD-1) receptor plays a major physiological role in the maintenance of immune tolerance and, by interaction with its ligands (PD-L1 and PD-L2), prevents the development of multiple immune-mediated diseases. There is growing evidence of the PD-1/PD-L1 pathway playing an importa...